Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

Abstract Background Tumor necrosis factor inhibitors (TNFi) are common second-line treatments for rheumatoid arthritis (RA). This study was designed to compare the real-world clinical and economic outcomes between patients with RA who responded to TNFi therapy and those who did not. Methods For this...

Full description

Bibliographic Details
Main Authors: Michael Grabner, Natalie N. Boytsov, Qing Huang, Xiang Zhang, Tingjian Yan, Jeffrey R. Curtis
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Arthritis Research & Therapy
Subjects:
Healthcare resource use
Healthcare costs
Biologic
Real-world observational study
Treatment response
Rheumatoid arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-017-1293-1

Internet

http://link.springer.com/article/10.1186/s13075-017-1293-1

Similar Items